Yuyu Pharma, Inc.

Quick facts

Phase 3 pipeline

• YY-162 · Diabetes
  YY-162 is a small molecule that targets the SGLT2 receptor.

Phase 2 pipeline

• YY-351

Phase 1 pipeline

• Maxmarvil®
• YY-201

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Yuyu Pharma, Inc. portfolio CI brief
• Yuyu Pharma, Inc. pipeline updates RSS